Update on ICOS: A Possible Target for Turning-Off Autoimmunity

Author(s): Priya Sakthivel

Journal Name: Recent Patents on Endocrine, Metabolic & Immune Drug Discovery
Continued as New Advances on Endocrine Metabolic and Immune Diseases

Volume 3 , Issue 3 , 2009


Inducible Co-stimulator (ICOS) is one of the co-stimulatory molecules that are unregulated within hours after TCR engagement. The interaction between ICOS and its ligand ICOSL positively co-stimulates T cell activation and proliferation. Thus, ICOS/ICOSL pathway contributes to one of the predisposing factors for autoimmune condition. Therefore, the positive co-stimulatory properties of ICOS are now being regarded as a possible and potential target for treating autoimmune disorders. Several in vivo studies have confirmed the amelioration of autoimmune disease by targeting ICOS pathway. This mini-review comprehensively describes the updated issues regarding ICOS from their discovery and functional consequences (at both genetic and protein aspects) to the recent patents in targeting ICOS pathway for turning-off immune responses in autoimmunity.

Keywords: ICOS, ICOSL (B7RP-1), co-stimulatory molecules, autoimmune disease

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2009
Published on: 01 March, 2012
Page: [205 - 213]
Pages: 9
DOI: 10.2174/187221409789104755
Price: $65

Article Metrics

PDF: 8